ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. - Wikidata - wikimedia - TriplyDB

ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.

ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.

http://www.wikidata.org/entity/Q44370637

about

Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity Disorder Associations of sleep disturbance with ADHD: implications for treatment A review of long-acting medications for ADHD in Canada Methylphenidate enhances prepulse inhibition during processing of task-relevant stimuli in attention-deficit/hyperactivity disorder.Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.Inhibitory functioning across ADHD subtypes: recent findings, clinical implications, and future directions.Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children.Attention deficit/hyperactivity disorder: pharmacotherapy.Open-label use of placebos in the treatment of ADHD: a pilot study.Using the ASEBA to Screen for Callous Unemotional Traits in Early Childhood: Factor Structure, Temporal Stability, and Utility.Parent and teacher ratings of attention during a year-long methylphenidate trial in children treated for cancer Growth on stimulant medication; clarifying the confusion: a review.Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression.Drug therapy of attention deficit hyperactivity disorder: current trends.New drugs for the treatment of attention-deficit/hyperactivity disorder.The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study Osmotic, controlled-release methylphenidate for the treatment of ADHD.The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy.Effects of Methylphenidate on Sleep Functioning in Children with Attention-Deficit/Hyperactivity Disorder Diagnostic and treatment challenges of chronic fatigue syndrome: role of immediate-release methylphenidate.Improving psychostimulant adherence in children with ADHD.Safety of medicines used for ADHD in children: a review of published prospective clinical trials.A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.Long-acting stimulants: development and dosing.Influence of methylphenidate on eating in obese men.Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study.

P2860

Q22241421-ED6A31A3-0038-4826-90B1-F1A9F9E2136A Q27027062-799E590E-32F3-4E7D-88B8-FB785EC28543 Q28263326-3861AD12-BC0C-42BE-AAEE-D0C1CBB45137 Q30474407-DCB69FFA-E445-4E7D-A381-4BEB559576BE Q33746664-F6585457-C654-425F-B8CD-F43A2F28A0DB Q33870580-A039F1E8-A565-4C3A-B7C7-5DD4D3B9F820 Q34021980-41EBBDBA-A048-4602-9444-EAC3A8790640 Q34040074-BE85B87C-B35C-40FC-8796-A665CDA130CE Q34303865-B0D0FD7B-7803-40AB-AF93-D521E28D0A4C Q34418634-8AB6C319-7A65-4476-B121-1EF0B58B10CF Q34732633-7F02835E-F5B8-43E2-9BE5-3F2B805DCD3A Q34772350-294B1B4F-A2B1-4C28-9E5A-B582F645713F Q35047116-945CFFC5-ED8F-4953-95C8-D8BEA79E7869 Q35284563-E89B44EE-D0BB-4885-B867-6156C3399EFB Q35483556-7B6E96D8-1640-4F39-AA56-0277839BE9CC Q35964370-A65CCC65-43E3-441E-9EDD-65EA085F9D68 Q35967393-592F9B10-3B26-4DAB-807E-16B50A709392 Q36082025-ABD7304D-C077-4659-B46F-1E8C9DDAE8F9 Q36229931-1F3AB464-6F25-4F07-B8D9-AC08120A9DD5 Q36613947-110A2863-E670-4B12-9137-F93C4D66C62B Q36699910-31038C59-8845-43DE-A2DF-A8C6253757C9 Q36952114-11BAF013-852A-41F0-A931-AFCD974257FC Q37174049-92B22BC5-58D4-491B-9594-A456067AFA30 Q37301222-14FE1FB4-0FA7-41AA-A72E-EAF5A88E92C6 Q38205749-1B216819-9B48-4A67-BEF4-C63936BC3AB4 Q38239633-AE9FD10D-B076-450C-B1A3-7AA06D26ED8E Q39040595-9BC47B70-9DB2-4288-98EF-04E4D270F4FB Q42761512-8214A15D-8947-4F32-86CA-FA4F40C45AAE Q44774930-25B962A7-7F07-4EAF-9CD4-B38226EA1CD7 Q50302223-52D3881C-8A8D-4905-B252-4EBC5FA7632C

P2860

ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.

http://www.wikidata.org/entity/Q44370637

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

ADHD treatment with once-daily ...... a long-term open-label study.

@en

ADHD treatment with once-daily ...... a long-term open-label study.

@nl

type

label

ADHD treatment with once-daily ...... a long-term open-label study.

@en

ADHD treatment with once-daily ...... a long-term open-label study.

@nl

prefLabel

ADHD treatment with once-daily ...... a long-term open-label study.

@en

ADHD treatment with once-daily ...... a long-term open-label study.

@nl

P1433

Q44370637-AC5CB935-8B11-459E-9B31-EB62CE569A1C

P1476

Q44370637-6F5900A7-99A6-4AA1-A213-C0EDCE2F2E5B

P2093

Q44370637-0C40DA2A-2391-4292-BB7C-35B2AE4D155B

Q44370637-1584821C-B7AB-43BF-992D-B28D6C128CC1

Q44370637-21F5C32A-5865-45BC-8F0F-B92660F7B27E

Q44370637-2CD205EE-4E5F-4F73-8133-3CC4468C6564

Q44370637-2F1E2A24-DB18-4946-A75B-B0EF2C0B7EBD

Q44370637-3C124EE4-F487-4D4D-8761-57379CDCA7CA

Q44370637-436C0E92-A649-4E88-88D6-8E42401082B6

Q44370637-73D7F6AB-0EFB-49AE-97A9-55ACB6E5ABAD

Q44370637-83CC4D94-9CE1-4F4E-885A-436B0E05759D

Q44370637-94303F19-68A3-4899-AF88-1CB5C6461CE0

P304

Q44370637-CF67D4DF-F69D-4666-95F2-BA5A701B25FF

P31

Q44370637-D16C874D-B22D-4D1D-B1AE-389CA49F60C0

P356

Q44370637-E0A995CA-2C96-4B8F-8A37-856017D91BDD

P433

Q44370637-A0C6D6CC-BECA-49E5-8ECC-F1ECEE5C71DC

P478

Q44370637-940B5909-7A52-4D71-8FC2-CB94A374462B

P577

Q44370637-75CA50C5-11C5-4A32-8744-223EF469A923

P698

Q44370637-EC642233-BBE1-43BC-8E4F-921A251E7C36

P356

01.CHI.0000046814.95464.7D

P1433

Journal of the American Academy of Child and Adolescent Psychiatry

P1476

ADHD treatment with once-daily ...... a long-term open-label study.

@en

P2093

C Keith Conners

http://www.w3.org/2001/XMLSchema#string

Donna Palumbo

http://www.w3.org/2001/XMLSchema#string

Gerald August

http://www.w3.org/2001/XMLSchema#string

Howard Abikoff

http://www.w3.org/2001/XMLSchema#string

James Swanson

http://www.w3.org/2001/XMLSchema#string

Keith McBurnett

http://www.w3.org/2001/XMLSchema#string

Laurence Greenhill

http://www.w3.org/2001/XMLSchema#string

Marc Atkins

http://www.w3.org/2001/XMLSchema#string

Mark Stein

http://www.w3.org/2001/XMLSchema#string

Mark Wolraich

http://www.w3.org/2001/XMLSchema#string

P304

424-433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.CHI.0000046814.95464.7D

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12649629

http://www.w3.org/2001/XMLSchema#string